Compare NBN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBN | DSGN |
|---|---|---|
| Founded | 1872 | 2017 |
| Country | United States | United States |
| Employees | 234 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 860.7M |
| IPO Year | N/A | 2021 |
| Metric | NBN | DSGN |
|---|---|---|
| Price | $131.78 | $15.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $130.50 | $15.25 |
| AVG Volume (30 Days) | 139.8K | ★ 997.7K |
| Earning Date | 04-27-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.77 | N/A |
| Revenue Next Year | $18.72 | N/A |
| P/E Ratio | $11.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $80.75 | $3.76 |
| 52 Week High | $142.31 | $17.25 |
| Indicator | NBN | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 64.80 |
| Support Level | $115.49 | $9.78 |
| Resistance Level | $137.08 | $17.10 |
| Average True Range (ATR) | 3.63 | 1.09 |
| MACD | -0.30 | 0.17 |
| Stochastic Oscillator | 53.05 | 78.51 |
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.